Skip to main content

Oligonucleotide API Manufacturing

Accelerate Your Journey from Clinical to Market

Partnering with Agilent, an experienced contract development and manufacturing organization, will give you the confidence that your clinical and commercial oligonucleotide API will meet appropriate specifications, quality, and purity requirements.

In two state-of-the art cGMP facilities in Colorado, U.S., Agilent produces grams to kilograms of siRNA, antisense, aptamers, gRNA, and other oligos. We are expanding capacity to take on more programs, increase batch sizes, and address our partners’ needs more quickly.

Agilent supports six commercial programs; you can rely on our expertise throughout clinical trials and commercialization. Accelerate speed to clinic and market, scale chemical processes, and produce high-quality oligo API with us.
Contact Us
+1 866-744-7638

Refine By



Sort Alphabetically

Filter by
Filter Content Selection Tool

Need Help? Find products using our Selection Tool.

Featured Literature

Accelerate Your Journey from Clinic to Market

Produce high-quality oligo APIs and efficiently advance from clinic to market, delivering therapeutics to patients with unmet medical needs

Agilent ClinGuide CRISPR sgRNA for Human Therapeutics

Accelerate the clinical success of therapeutic gene editing programs.

Featured Videos
Return to top
Featured News

Colorado Governor Polis Helps Agilent Break Ground on $725 Million Expansion of Manufacturing Operations in Frederick

Agilent leaders joined Colorado Governor Jared Polis and local government officials to break ground on $725 million investment to double manufacturing capacity of therapeutic nucleic acids in Frederick, Colorado. The investment will create more than 160 life science jobs in the area. Agilent’s manufacturing facilities in Colorado produce siRNA, antisense molecules, and CRISPR guide RNA molecules.

Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics

Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases. The addition of two new manufacturing lines (known as Trains C and D) will enable Agilent to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules. Agilent expects customer shipments from the expansion to begin in 2026.

0 product selected.

Clear All